108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
膀胱癌患者尿路感染的影响因素及风险预测模型构建
Authors Di Y, Zhang L, Zhao L, Yin L
Received 5 June 2025
Accepted for publication 15 September 2025
Published 30 September 2025 Volume 2025:17 Pages 383—399
DOI https://doi.org/10.2147/RRU.S545001
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Guglielmo Mantica
Yancheng Di, Lingling Zhang, Linlin Zhao, Lei Yin
Department of Urology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, 157000, People’s Republic of China
Correspondence: Lei Yin, Department of Urology, Hongqi Hospital Affiliated to Mudanjiang Medical University, No. 5 Tongxiang Road, Aimin District, Mudanjiang, 157000, People’s Republic of China, Email 13394534600@163.com
Purpose: Urinary tract infections (UTI) are a common complication in patients with bladder cancer (BLCA). This study investigated the role of stearoyl-CoA desaturase-1 (SCD1) in BLCA progression and assessed its potential as a biomarker for predicting UTI risk in BLCA patients.
Patients and Methods: SCD1 expression profiles were evaluated in BLCA patients with concurrent UTI. Receiver operating characteristic curve analysis was used to assess the diagnostic value of SCD1 for predicting UTI risk. In vitro assays were conducted to explore the functional role of SCD1 in lipopolysaccharide (LPS)-associated BLCA progression.
Results: SCD1 expression was significantly higher in the UTI group compared with the non-UTI group (p = 0.000 and 0.011, respectively). The combination of SCD1, immune-inflammation index, and C-reactive protein demonstrated strong predictive value for UTI risk in BLCA patients (non-muscle invasive BLCA patients: area under the curve (AUC) = 0.887; 95% CI: 0.821– 0.935; muscle-invasive BLCA patients: AUC = 0.861; 95% CI: 0.767– 0.927). Functional experiments revealed that lipopolysaccharide (LPS)-induced SCD1 expression promoted autophagy and enhanced malignant phenotypes, whereas SCD1 inhibition or treatment with an autophagosome inhibitor reversed these effects.
Conclusion: SCD1 promotes LPS-associated BLCA progression by regulating autophagy and may serve as a valuable biomarker for predicting UTI risk in BLCA patients.
Keywords: bladder cancer, urinary tract infections, stearoyl-CoA desaturase 1, autophagy, biomarker
Department of Urology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, 157000, People’s Republic of China
Correspondence: Lei Yin, Department of Urology, Hongqi Hospital Affiliated to Mudanjiang Medical University, No. 5 Tongxiang Road, Aimin District, Mudanjiang, 157000, People’s Republic of China, Email 13394534600@163.com
Purpose: Urinary tract infections (UTI) are a common complication in patients with bladder cancer (BLCA). This study investigated the role of stearoyl-CoA desaturase-1 (SCD1) in BLCA progression and assessed its potential as a biomarker for predicting UTI risk in BLCA patients.
Patients and Methods: SCD1 expression profiles were evaluated in BLCA patients with concurrent UTI. Receiver operating characteristic curve analysis was used to assess the diagnostic value of SCD1 for predicting UTI risk. In vitro assays were conducted to explore the functional role of SCD1 in lipopolysaccharide (LPS)-associated BLCA progression.
Results: SCD1 expression was significantly higher in the UTI group compared with the non-UTI group (p = 0.000 and 0.011, respectively). The combination of SCD1, immune-inflammation index, and C-reactive protein demonstrated strong predictive value for UTI risk in BLCA patients (non-muscle invasive BLCA patients: area under the curve (AUC) = 0.887; 95% CI: 0.821– 0.935; muscle-invasive BLCA patients: AUC = 0.861; 95% CI: 0.767– 0.927). Functional experiments revealed that lipopolysaccharide (LPS)-induced SCD1 expression promoted autophagy and enhanced malignant phenotypes, whereas SCD1 inhibition or treatment with an autophagosome inhibitor reversed these effects.
Conclusion: SCD1 promotes LPS-associated BLCA progression by regulating autophagy and may serve as a valuable biomarker for predicting UTI risk in BLCA patients.
Keywords: bladder cancer, urinary tract infections, stearoyl-CoA desaturase 1, autophagy, biomarker